Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.
Myriam ChalabiYara L VerschoorPedro Batista TanSara BalduzziAnja U Van LentCecile GrootscholtenSimone DokterNikè V BüllerBrechtje A GrotenhuisKoert KuhlmannJacobus W BurgerInge L HuibregtseTjeerd S AukemaEduard R HendriksSteven J OosterlingPetur SnaebjornssonEmile E VoestLodewyk F WesselsRegina G Beets-TanMonique E Van LeerdamTon N SchumacherJosé G van den BergGeerard L BeetsJohn B HaanenPublished in: The New England journal of medicine (2024)
In patients with locally advanced dMMR colon cancer, neoadjuvant nivolumab plus ipilimumab had an acceptable safety profile and led to a pathological response in a high proportion of patients. (Funded by Bristol Myers Squibb; NICHE-2 ClinicalTrials.gov number, NCT03026140.).